Available BMT CTN Studies

Please navigate within the drop downs on this page to learn about the available BMT CTN studies. 

Here are the active studies by disease type or condition: 

Bone marrow transplant for untreated severe aplastic anemia (BMT CTN 2207; CureAA)

  • Study Goal: to find out if bone marrow transplant works as the first treatment for people diagnosed with severe aplastic anemia
  • Patient Summary: coming soon
  • Patient Consent Form: coming soon
  • Status: The study will be open to patients in the summer of 2024. More information will be available soon.

For additional clinical trials for aplastic anemia, Visit Here.

Three drugs, treosulfan, fludarabine and lapine T-lymphocyte immune globulin (rATG), before allogeneic (cells from a donor) blood or marrow transplant to treat bone marrow failure disorders in children, teens and adults (BMT CTN 1904)

  • This study is for people with bone marrow failure disorders such as: 
    • Congenital amegakaryocytic thrombocytopenia (CAMT)
    • Congenital sideroblastic anemia (CSA)
    • Diamond Blackfan anemia (DFA)
    • GATA2 deficiency
    • Paroxysmal nocturnal hemoglobinuria (PNH)
    • SAMD9 disorder
    • SAMD9L disorder
    • Shwachman-Diamond syndrome (SDS)
    • Other bone marrow failure disorder, even if the cause is unknown
  • Study goal: to find out if the adding the drug treosulfan to treatment before transplant will cause fewer complications and make transplant work better
  • Patient Consent Form
  • Status: The study is open to new patients
  • Eligibility and site location information
  • For More Info: Protocol (detailed study information)

For additional bone marrow failure clinical trials, Visit Here.
 

For additional information about sickle cell disease studies, Visit Here.

BMT CTN doesn’t have any current clinical trials for other diagnoses. To find open clinical trials, visit the NMDP Clinical Trials Search and Support website

Here are the active studies by transplant side effects: